Hydroxocobalamin for Empiric Treatment of Smoke Inhalation-Associated Cyanide Poisoning: Results of a Prospective Study in the Prehospital Setting

Abstract

Study Objectives: Hydroxocobalamin (vitamin B12a) is being investigated for possible introduction in the United States to address the unmet need for an antidote well-suited for empiric out-of-hospital intervention in cyanide poisoning including that caused by smoke inhalation. The antidotal efficacy of hydroxocobalamin for acute cyanide poisoning was assessed in a prospective, open-label study of smoke-inhalation victims in France, where hydroxocobalamin was granted regulatory approval for marketing in 1996.